Biolargo director granted 40,909 stock options

BIOLARGO, INC. director Marshall Dennis E received a new stock option grant as part of his board compensation.

Rhea-AI Filing Summary

BIOLARGO, INC. director Marshall Dennis E received a new stock option grant as part of his board compensation. On June 22, 2026, he was awarded options to purchase 40,909 shares of common stock at an exercise price of $0.11 per share, expiring June 22, 2036. The grant replaces a prior option for 10,000 shares that expired unexercised, and his total option holdings after this adjustment are 5,463,738 options.

Insider Trade Summary

Grant/Award: 40,909 shares

Grant/Award 1 txn

Insider Marshall Dennis E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	40,909	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 5,463,738 contracts (Direct)

Footnotes (2)

1. F1. This Option was granted to Reporting Person to replace an option to purchase 10,000 shares that had been issued to compensate Reporting Person for services on the board of directors to the Issuer and had expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
2. F2. Total reflects the expiration of options to purchase 10,000 shares that expired June 20, 2026.

Key Figures

Option grant size: 40,909 options Exercise price: $0.11 per share Expiration date: June 22, 2036 +2 more

5 metrics

Option grant size 40,909 options Grant on June 22, 2026 for board compensation

Exercise price $0.11 per share Exercise price of new options

Expiration date June 22, 2036 Expiration of new option grant

Total options after grant 5,463,738 options Total derivative holdings following transaction

Expired prior option 10,000 options Prior option that expired June 20, 2026

Key Terms

Option to Purchase Common Stock, Grant, award, or other acquisition, Compensation Committee, exercise price

4 terms

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Compensation Committee financial

"pursuant to plan adopted by the Issuer's Compensation Committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

exercise price financial

"a discrepancy between the original exercise price and Issuer's current stock price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BIOLARGO (BLGO) director Marshall Dennis E receive in this Form 4 filing?

He received a new stock option grant for 40,909 shares of BIOLARGO common stock. This award compensates him for board service and is reflected as a routine grant/award acquisition under the company’s compensation plan.

What is the exercise price and term of the new BIOLARGO (BLGO) stock options?

The new options have an exercise price of $0.11 per share and expire on June 22, 2036. This gives the director a long exercise window typical of equity compensation for board service.

How many BIOLARGO (BLGO) options does Marshall Dennis E hold after this transaction?

After the grant, he holds a total of 5,463,738 stock options. This figure reflects the addition of 40,909 new options and the expiration of a prior 10,000‑share option that was not exercised.

Did Marshall Dennis E buy or sell any BIOLARGO (BLGO) shares in this Form 4?

No open‑market buying or selling occurred; the filing reports a grant of stock options. The transaction code “A” indicates a grant or award, not a market purchase or sale of existing shares.

Why was a new BIOLARGO (BLGO) option granted to replace a prior one?

The new option replaced a 10,000‑share option that expired unexercised due to a discrepancy between its original exercise price and BIOLARGO’s current stock price, under a plan adopted by the Compensation Committee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marshall Dennis E

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.11	06/22/2026		A		40,909		06/22/2026	06/22/2036	Common Stock	40,909	(1)	5,463,738(2)	D

Explanation of Responses:

1. This Option was granted to Reporting Person to replace an option to purchase 10,000 shares that had been issued to compensate Reporting Person for services on the board of directors to the Issuer and had expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.

2. Total reflects the expiration of options to purchase 10,000 shares that expired June 20, 2026.

	/s/ John R. Browning, attorney-in-fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)